Wall Street analysts predict that Cue Biopharma Inc (NASDAQ:CUE) will report earnings per share of ($0.44) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Cue Biopharma’s earnings. Cue Biopharma posted earnings per share of ($0.62) in the same quarter last year, which indicates a positive year over year growth rate of 29%. The company is scheduled to issue its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Cue Biopharma will report full-year earnings of ($1.96) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of ($1.35) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Cue Biopharma.
Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.10. Cue Biopharma had a negative net margin of 2,039.41% and a negative return on equity of 151.93%. The business had revenue of $1.06 million during the quarter.
Several research analysts have recently commented on the stock. Robert W. Baird assumed coverage on shares of Cue Biopharma in a research note on Thursday, July 25th. They issued an “outperform” rating and a $13.00 price objective for the company. ValuEngine lowered shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday.
Shares of NASDAQ CUE traded up $0.02 during midday trading on Thursday, hitting $8.82. The company’s stock had a trading volume of 100,500 shares, compared to its average volume of 86,567. The business’s fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $8.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.65 and a quick ratio of 2.65. Cue Biopharma has a 1 year low of $4.16 and a 1 year high of $9.94. The firm has a market capitalization of $185.61 million, a price-to-earnings ratio of -4.54 and a beta of 1.19.
Institutional investors have recently modified their holdings of the stock. Sigma Planning Corp purchased a new stake in shares of Cue Biopharma during the 1st quarter worth approximately $325,000. Strs Ohio lifted its position in shares of Cue Biopharma by 500.0% during the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after buying an additional 12,500 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Cue Biopharma by 1,159.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock worth $29,000 after buying an additional 3,503 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Cue Biopharma by 33.8% during the 2nd quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock worth $5,504,000 after buying an additional 154,639 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Cue Biopharma by 21.3% during the 2nd quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock worth $10,321,000 after buying an additional 201,986 shares during the last quarter. Institutional investors own 19.93% of the company’s stock.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Featured Article: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.